Pelthos and Castle Creek agree biotechnology merger with up to $300 million in contingent milestone payments

Pelthos Therapeutics and Castle Creek Biosciences have agreed to merge, combining a dermatology portfolio with a fibroblast-based cell and gene therapy platform for serious skin diseases.

The proposed transaction, announced on 30 October 2026, would bring Castle Creek's investigational D-Fi programme for dystrophic epidermolysis bullosa into the combined business, with Castle Creek shareholders receiving 5.2 million Pelthos shares representing approximately 32.5% of fully diluted ownership at closing.

Additional consideration could include up to 5.8 million shares and as much as $300 million in contingent milestone payments, with closing expected by the end of the first quarter of 2027 subject to customary conditions.

Field	Content
Article Type	Deals
Companies	Pelthos Therapeutics; Castle Creek Biosciences
Deal Type	Definitive biotechnology merger agreement
Announcement Date	30 October 2026
Transaction Status	Announced; closing pending
Expected Closing	By the end of the first quarter of 2027
Therapeutic Area	Dermatology; rare genetic skin diseases
Combined Portfolio Focus	Dermatology products and investigational cell and gene therapies
Acquired Technology Platform	Fibroblast-based cell and gene therapy
Lead Investigational Programme	D-Fi
Target Indication	Dystrophic epidermolysis bullosa
Programme Regulatory Status	Investigational; no new marketing approval announced
Initial Share Consideration	5.2 million Pelthos shares
Expected Castle Creek Shareholder Ownership	Approximately 32.5% on a fully diluted basis at closing
Potential Additional Share Consideration	Up to 5.8 million shares
Potential Contingent Milestone Payments	Up to $300 million
Milestone Payment Clarification	Contingent consideration; not an upfront cash payment
Closing Conditions	Subject to customary transaction closing conditions
What Happened	Pelthos and Castle Creek entered a definitive merger agreement combining dermatology assets with a fibroblast-based cell and gene therapy platform.
Why It Matters	The merger could broaden the combined company's dermatology portfolio into advanced therapies for serious genetic skin diseases.
Strategic Rationale	Integrate commercial dermatology capabilities with Castle Creek's investigational cell and gene therapy programmes.
Financial Structure	Initial equity consideration plus potential additional shares and up to $300 million in contingent milestone payments.
Key Takeaway	The merger is proposed rather than completed, with significant additional consideration dependent on future milestones.
What to Watch	Transaction approvals, closing by the first quarter of 2027, D-Fi development progress, integration plans and milestone achievement.
Primary Source	Pelthos Therapeutics SEC filing
Primary Source URL	https://ir.pelthos.com/sec-filings/all-sec-filings/content/0001104659-26-120458/tm2628523d2_ex99-1.htm
Relevant Date	30 October 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com